



Press Release

Tuesday, July 27, 2010

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

Strides today announced Q2-10 results
“Delivers Record Performance”

Revenue up 56% and EBITDA up 278% for Q2-10
and
Revenue up 44% and EBITDA up 157% for H1-10

Q2 - 10 Financial results


(Source Q2-10 consolidated unaudited results)

Revenues at Rs.484 Crores (Rs.311 Crores in Q2-09)	Up 56 %
EBITDA at Rs. 131 Crores (Rs 34 Crores in Q2-09)	Up 278%
Improved EBITDA Margin from 11% to 27 %	Up 145%
PBT at Rs. 59 Crores (Rs.51 Crores in Q2-09)	Up 15 %
PAT after Minority at Rs. 46 Crores (Rs.42 Crores in Q2-09)	Up 10 %
EPS for Q2-10	Rs 10.33

H1 - 10 Financial results

(Source H1-10 consolidated unaudited results)

Revenues at Rs.865 Crores (Rs.603 Crores in H1-09)	Up 44 %
EBITDA at Rs. 216 Crores (Rs.84 Crores in H1 -09)	Up 157%
Improved EBITDA Margin from 14% to 25 %	Up 79%
PBT at Rs. 109 Crores (Rs.62 Crores in H1-09)	Up 76 %
PAT after Minority at Rs. 86 Crores (Rs.52 Crores in H1-09)	Up 64 %
EPS for H1-10	Rs 19.78



Highlights for the quarter

- ✓ Strides and Pfizer Strengthened Partnership
 - Extended Oncology agreement to Europe, Canada, Australia, New Zealand, Japan and Korea
 - Entered into an agreement for niche sterile injectables for the US market
- ✓ Redeemed FCCBs worth USD 34 Million in April 2010 (total payout of USD 47 Million)
- ✓ Received LACP 'Platinum' Award for the best annual report in the Pharma (USD 100 to USD 1 Billion) category

Regulatory Approval Status


- ✓ Received 14 ANDA approvals from USFDA, YTD 2010. Total approvals at 45, 27 in specialties
- ✓ 7 ANDA filings with USFDA, YTD 2010. Total filings at 132, 98 in specialties
- ✓ 87 pending approvals with USFDA, 71 pending in Specialties space
- ✓ Brazil, Poland, Oncology and Steriles new complex plants have received European approvals. Steriles new complex and Oncology plants have also received TGA approval.

Commenting on the performance, Mr. Arun Kumar, Group CEO said, "Our second quarter results are strong with Revenue and Margin at a historic high. I am delighted with the robust performance delivered by both Specialties and Pharma businesses in Q210 and H110."

Business-Wise Performance

Rs. Crores

Business	Revenues				EBITDA			
	Q2'2010	%	Q2'2009	Growth %	Q2'2010	%	Q2'2009	Growth %
Specialties	221	46	74	200%	108	82%	19	468%
Pharma	263	54	237	11%	23	18%	15	53%
Reported Financials	484		311	56%	131		34	278%



- ✓ Consolidated Revenues include R&D and Licensing Income of Rs.135 crores in both Sterile and Pharma

Business-Wise Performance

Rs. Crores

Business	Revenues				EBITDA			
	H1'2010	%	H1'2009	Growth %	H1'2010	%	H1'2009	Growth %
Specialties	344	40	170	102	151	70	40	278
Pharma	521	60	433	20	65	30	44	48
Reported Financials	865		603	44	216		84	157

- ✓ Consolidated Revenues include R&D and Licensing Income of Rs.218 crores in both Sterile and Pharma

Key growth drivers:

Specialties


The growth in Specialties Business has been driven by continuing licensing income and new product launches in the regulated markets.

Pharma

The growth in Pharma business has been driven by a strong performance in the Australasia Region. The Company also, post the integration of its Indian operations, continues to build a strong brand business and has successfully addressed all legacy issues.

Strides Arcolab Limited: Leadership through Partnering

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables. The Company has 14 manufacturing facilities across 6 countries and has a marketing presence in more than 60 countries in developed and emerging markets. Manufacturing is ably supported by a 350-



scientist strong global R&D Centre located in Bangalore. Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

<p><u>Strides</u></p> <p>Mr. T.S. Rangan, Group CFO +91 80 66580115</p> <p>Mr. Kannan. N (Investors) +91 98450 54745</p> <p>Melissa Arulappan (Media) +91 98450 22389</p>	<p><u>PR Consultancy</u></p> <p>Mahesh Nair, Corporate Voice/Weber Shandwick +91 9880376648 maheshn@corvoshandwick.co.in</p> <p>Kasturi Wasmatkar +91 9916728393 kasturi@corvoshandwick.co.in</p>
--	--

